keyword
MENU ▼
Read by QxMD icon Read
search

BCG prime

keyword
https://www.readbyqxmd.com/read/28161464/mycobacterium-tuberculosis-proteins-involved-in-cell-wall-lipid-biosynthesis-improve-bcg-vaccine-efficacy-in-a-murine-tb-model
#1
REVIEW
Martin Rao, Nathalie Cadieux, Megan Fitzpatrick, Steven Reed, Sergei Arsenian, Davide Valentini, Shreemanta Parida, Ernest Dodoo, Alimuddin Zumla, Markus Maeurer
OBJECTIVES: Advances in tuberculosis (TB) vaccine development are urgently required to enhance global disease management. We evaluated the potential of Mycobacterium tuberculosis (M. tb)-derived protein antigens Rv0447c, Rv2957 and Rv2958c to boost BCG vaccine efficacy in the presence or absence of glucopyranosyl lipid adjuvant formulated in a stable emulsion (GLA-SE) adjuvant. METHODS: Mice received the BCG vaccine, followed by Rv0447c, Rv2957 and Rv2958c protein boosting with or without GLA-SE adjuvant 3 and 6 weeks later...
February 1, 2017: International Journal of Infectious Diseases: IJID
https://www.readbyqxmd.com/read/28123491/ag85b-synergizes-with-esat-6-to-induce-efficient-and-long-term-immunity-of-c57bl-6-mice-primed-with-recombinant-bacille-calmette-guerin
#2
Wei Liu, Ying Xu, Jingran Yan, Hongbo Shen, Enzhuo Yang, Honghai Wang
The latest probable scenario in vaccination strategies is to prime one live attenuated vaccine candidate followed by boost dose of second vaccine candidate. In the present study, we primed the mice with a recombinant Bacille Calmette-Guerin (BCG) comprising Ag85B and ESAT-6 followed by boost doses of Ag85B, ESAT-6 and Ag85B-ESAT-6 fusion protein in the DDA adjuvant, separately. After boost doses of 8 and 12 weeks, the levels of antigen-stimulated T cells secreting interferon (IFN)-γ, the content of the IFN-γ, tumor necrosis factor-α and interleukin-4 in the splenocytes in vitro culture supernatant, the antigen-specific immunoglobulin (Ig)G titer from mouse serum, IgG subclass and the population of antigen-specific CD4(+) and CD8(+) T cells were detected...
January 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28087924/clinical-testing-of-tuberculosis-vaccine-candidates
#3
Mark Hatherill, Dereck Tait, Helen McShane
It is almost 100 years since the development of bacille Calmette-Guérin (BCG), the only licensed vaccine against tuberculosis (TB). While BCG does confer consistent protection against disseminated disease, there is an urgent need for a more effective vaccine against pulmonary disease. There are several indications for such an improved vaccine, including prevention of infection, prevention of disease, and a therapeutic vaccine to prevent recurrent disease. The two main approaches to TB vaccine development are developing an improved whole mycobacterial priming agent to replace BCG and/or developing a subunit booster vaccine to be administered after a BCG or BCG replacement priming vaccination...
October 2016: Microbiology Spectrum
https://www.readbyqxmd.com/read/28011813/does-oral-polio-vaccine-have-non-specific-effects-on-all-cause-mortality-natural-experiments-within-a-randomised-controlled-trial-of-early-measles-vaccine
#4
Peter Aaby, Andreas Andersen, Cesário L Martins, Ane B Fisker, Amabelia Rodrigues, Hilton C Whittle, Christine S Benn
BACKGROUND: BCG and measles vaccine (MV) may have beneficial non-specific effects (NSEs). If an unplanned intervention with a vaccine (a natural experiment) modifies the estimated effect in a randomised controlled trial (RCT), this suggests NSEs. We used this approach to test NSEs of triple oral polio vaccine (OPV). METHODS: During an RCT of 2 doses of MV at 4.5 and 9 months versus 1 dose of MV at 9 months of age, we experienced 2 natural experiments with OPV...
December 23, 2016: BMJ Open
https://www.readbyqxmd.com/read/27997597/immunogenicity-and-protective-efficacy-of-the-dar-901-booster-vaccine-in-a-murine-model-of-tuberculosis
#5
Timothy Lahey, Dominick Laddy, Krystal Hill, Jacqueline Schaeffer, Alison Hogg, James Keeble, Belinda Dagg, Mei Mei Ho, Robert D Arbeit, C Fordham von Reyn
BACKGROUND: The development of a novel tuberculosis vaccine is a leading global health priority. SRL172, an inactivated, whole-cell mycobacterial vaccine, was safe, immunogenic and reduced the incidence of culture-confirmed tuberculosis in a phase III trial in HIV-infected and BCG immunized adults in Tanzania. Here we describe the immunogenicity and protective efficacy of DAR-901, a booster vaccine against tuberculosis manufactured from the same seed strain using a new scalable method...
2016: PloS One
https://www.readbyqxmd.com/read/27960596/heterologous-boosting-with-recombinant-vsv-846-in-bcg-primed-mice-confers-improved-protection-against-mycobacterium-infection
#6
Ming Zhang, Chunsheng Dong, Sidong Xiong
Tuberculosis (TB) remains a major health problem worldwide, and the development of effective vaccines is urgently needed. Vaccination strategies based on heterologous prime-boost protocols using Mycobacterium bovis bacillus Calmette-Guérin (BCG) as primer and modified vaccinia virus Ankara strain expressing the mycobacterial antigen Ag85A (MVA85A) as booster may increase the protective efficacy of BCG. In addition, vaccination with the recombinant viral vaccine vesicular stomatitis virus (VSV)-846 (Rv3615c, Mtb10...
December 14, 2016: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/27941982/overexpression-of-a-mycobacterium-ulcerans-ag85b-esxh-fusion-protein-in-recombinant-bcg-improves-experimental-buruli-ulcer-vaccine-efficacy
#7
Bryan E Hart, Sunhee Lee
Buruli ulcer (BU) vaccine design faces similar challenges to those observed during development of prophylactic tuberculosis treatments. Multiple BU vaccine candidates, based upon Mycobacterium bovis BCG, altered Mycobacterium ulcerans (MU) cells, recombinant MU DNA, or MU protein prime-boosts, have shown promise by conferring transient protection to mice against the pathology of MU challenge. Recently, we have shown that a recombinant BCG vaccine expressing MU-Ag85A (BCG MU-Ag85A) displayed the highest level of protection to date, by significantly extending the survival time of MU challenged mice compared to BCG vaccination alone...
December 2016: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/27865389/mycobacterium-indicus-pranii-as-a-booster-vaccine-enhances-bcg-induced-immunity-and-confers-higher-protection-in-animal-models-of-tuberculosis
#8
Mohd Saqib, Rahul Khatri, Bindu Singh, Ananya Gupta, Arvind Kumar, Sangeeta Bhaskar
BCG, the only approved vaccine protects against severe form of childhood tuberculosis but its protective efficacy wanes in adolescence. BCG has reduced the incidence of infant TB considerably in endemic areas; therefore prime-boost strategy is the most realistic measure for control of tuberculosis in near future. Mycobacterium indicus pranii (MIP) shares significant antigenic repertoire with Mtb and BCG and has been shown to impart significant protection in animal models of tuberculosis. In this study, MIP was given as a booster to BCG vaccine which enhanced the BCG mediated immune response, resulting in higher protection...
December 2016: Tuberculosis
https://www.readbyqxmd.com/read/27823900/gene-based-neonatal-immune-priming-potentiates-a-mucosal-adenoviral-vaccine-encoding-mycobacterial-ag85b
#9
Guixiang Dai, Hamada F Rady, Weitao Huang, Judd E Shellito, Carol Mason, Alistair J Ramsay
Tuberculosis remains a major public health hazard worldwide, with neonates and young infants potentially more susceptible to infection than adults. BCG, the only vaccine currently available, provides some protection against tuberculous meningitis in children but variable efficacy in adults, and is not safe to use in immune compromised individuals. A safe and effective vaccine that could be given early in life, and that could also potentiate subsequent booster immunization, would represent a significant advance...
December 7, 2016: Vaccine
https://www.readbyqxmd.com/read/27799930/increased-tnf-%C3%AE-ifn-%C3%AE-il-2-and-decreased-tnf-%C3%AE-ifn-%C3%AE-production-by-central-memory-t-cells-are-associated-with-protective-responses-against-bovine-tuberculosis-following-bcg-vaccination
#10
Mayara F Maggioli, Mitchell V Palmer, Tyler C Thacker, Hans Martin Vordermeier, Jodi L McGill, Adam O Whelan, Michelle H Larsen, William R Jacobs, W Ray Waters
Central memory T cell (Tcm) and polyfunctional CD4 T cell responses contribute to vaccine-elicited protection with both human and bovine tuberculosis (TB); however, their combined role in protective immunity to TB is unclear. To address this question, we evaluated polyfunctional cytokine responses by CD4 T cell effector/memory populations from bacille Calmette-Guerin (BCG) vaccinated and non-vaccinated calves by flow cytometry prior to and after aerosol challenge with virulent Mycobacterium bovis. Polyfunctional cytokine expression patterns in the response by Tcm, effector memory, and effector T cell subsets were similar between BCG-vaccinated and M...
2016: Frontiers in Immunology
https://www.readbyqxmd.com/read/27733422/in-vitro-experimental-model-of-trained-innate-immunity-in-human-primary-monocytes
#11
Siroon Bekkering, Bastiaan A Blok, Leo A B Joosten, Niels P Riksen, Reinout van Crevel, Mihai G Netea
Innate immune memory, or trained immunity, has recently been described to be an important property of cells of the innate immune system. Due to the increased interest in this important new field of immunological investigation, we sought to determine the optimal conditions for an in vitro experimental protocol of monocyte training using three of the most commonly used training stimuli from the literature: β-glucan, the bacillus Calmette-Guérin (BCG) vaccine, and oxidized low-density lipoprotein (oxLDL). We investigated and optimized a protocol of monocyte trained immunity induced by an initial training period with β-glucan, BCG, or oxLDL, followed by washing and resting of the cells and, thereafter, restimulation with secondary bacterial stimuli...
December 2016: Clinical and Vaccine Immunology: CVI
https://www.readbyqxmd.com/read/27703038/induction-of-an-immune-protective-t-cell-repertoire-with-diverse-genetic-coverage-by-a-novel-viral-vectored-tuberculosis-vaccine-in-humans
#12
Mangalakumari Jeyanathan, Daniela Damjanovic, Yushi Yao, Jonathan Bramson, Fiona Smaill, Zhou Xing
BACKGROUND:  Whether a candidate tuberculosis vaccine induces clinically relevant protective T-cell repertoires in humans will not be known until the completion of costly efficacy clinical trials. METHODS:  We have developed an integrated immunologic approach to investigate the clinical relevance of T cells induced by a novel tuberculosis vaccine in a phase 1 trial. This approach consists of screening for likely dominant T-cell epitopes, establishing antigen-specific memory T-cell lines for identifying CD8(+) and CD4(+) T-cell epitopes, determining the ability of vaccine-induced T cells to inhibit mycobacterial growth in infected cells, and examining the genetic diversity of HLA recognition and the clinical relevance of identified T-cell epitopes...
December 15, 2016: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/27566581/mycobacterium-tuberculosis-multistage-antigens-confer-comprehensive-protection-against-pre-and-post-exposure-infections-by-driving-th1-type-t-cell-immunity
#13
Jilei Ma, Maopeng Tian, Xionglin Fan, Qi Yu, Yukai Jing, Weihua Wang, Li Li, Zijie Zhou
There is an urgent need for a vaccine against tuberculosis (TB) that is more effective than the current sole licensed option. However, target antigens of Mycobacterium tuberculosis with the vaccine potential remain elusive. Five immunodominant antigens with characteristic expressions at the stages of primary infection (Ag85A), the regulation of nutrition and metabolism when transferring from rapid growth to latency (PhoY2 and Rv3407), latency (Rv2626c), and reactivation (RpfB) were selected to construct the fusion polyprotein WH121, which has better immunogenicity and protection than each multistage antigen...
September 27, 2016: Oncotarget
https://www.readbyqxmd.com/read/27498622/protection-associated-with-a-tb-vaccine-is-linked-to-increased-frequency-of-ag85a-specific-cd4-t-cells-but-no-increase-in-avidity-for-ag85a
#14
Hannah J Metcalfe, Sabine Steinbach, Gareth J Jones, Tim Connelley, W Ivan Morrison, Martin Vordermeier, Bernardo Villarreal-Ramos
There is a need to improve the efficacy of Bacille Calmette-Guérin (BCG) vaccination against tuberculosis in humans and cattle. Previously, we found boosting BCG-primed cows with recombinant human type 5 adenovirus expressing antigen 85A (Ad5-85A) increased protection against Mycobacterium bovis infection compared to BCG vaccination alone. The aim of this study was to decipher aspects of the immune response associated with this enhanced protection. We compared BCG-primed Ad5-85A-boosted cattle with BCG-vaccinated cattle...
August 31, 2016: Vaccine
https://www.readbyqxmd.com/read/27450001/influence-of-phthiocerol-dimycocerosate-on-cd4-t-cell-priming-and-persistence-during-mycobacterium-tuberculosis-infection
#15
Rachel Pinto, Jonathan K Nambiar, Lisa Leotta, Claudio Counoupas, Warwick J Britton, James A Triccas
The characterisation of mycobacterial factors that influence or modulate the host immune response may aid the development of more efficacious TB vaccines. We have previously reported that Mycobacterium tuberculosis deficient in export of Phthiocerol Dimycocerosates (DIM) (MT103(ΔdrrC)) is more attenuated than wild type M. tuberculosis and provides sustained protective immunity compared to the existing BCG vaccine. Here we sought to define the correlates of immunity associated with DIM deficiency by assessing the impact of MT103(ΔdrrC) delivery on antigen presenting cell (APC) function and the generation of CD4(+) T cell antigen-specific immunity...
July 2016: Tuberculosis
https://www.readbyqxmd.com/read/27427967/hiv-1-subtype-c-mosaic-gag-expressed-by-bcg-and-mva-elicits-persistent-effector-t-cell-responses-in-a-prime-boost-regimen-in-mice
#16
Tsungai Ivai Jongwe, Ros Chapman, Nicola Douglass, Shivan Chetty, Gerald Chege, Anna-Lise Williamson
Over 90% of HIV/AIDS positive individuals in sub-Saharan Africa are infected with highly heterogeneous HIV-1 subtype C (HIV-1C) viruses. One of the best ways to reduce the burden of this disease is the development of an affordable and effective prophylactic vaccine. Mosaic immunogens are computationally designed to overcome the hurdle of HIV diversity by maximizing the expression of potential T cell epitopes. Mycobacterium bovis BCG ΔpanCD auxotroph and modified vaccinia Ankara (MVA) vaccines expressing HIV-1C mosaic Gag (GagM) were tested in a prime-boost regimen to demonstrate immunogenicity in a mouse study...
2016: PloS One
https://www.readbyqxmd.com/read/27317453/parenteral-adenoviral-boost-enhances-bcg-induced-protection-but-not-long-term-survival-in-a-murine-model-of-bovine-tb
#17
Daryan A Kaveh, M Carmen Garcia-Pelayo, Paul R Webb, Esen E Wooff, Véronique S Bachy, Philip J Hogarth
Boosting BCG using heterologous prime-boost represents a promising strategy for improved tuberculosis (TB) vaccines, and adenovirus (Ad) delivery is established as an efficacious boosting vehicle. Although studies demonstrate that intranasal administration of Ad boost to BCG offers optimal protection, this is not currently possible in cattle. Using Ad vaccine expressing the mycobacterial antigen TB10.4 (BCG/Ad-TB10.4), we demonstrate, parenteral boost of BCG immunised mice to induce specific CD8(+) IFN-γ producing T cells via synergistic priming of new epitopes...
July 25, 2016: Vaccine
https://www.readbyqxmd.com/read/27247233/targeting-mycobacterium-tuberculosis-tumor-necrosis-factor-alpha-downregulating-genes-for-the-development-of-antituberculous-vaccines
#18
Aaron Olsen, Yong Chen, Qingzhou Ji, Guofeng Zhu, Aruna Dharshan De Silva, Catherine Vilchèze, Torin Weisbrod, Weimin Li, Jiayong Xu, Michelle Larsen, Jinghang Zhang, Steven A Porcelli, William R Jacobs, John Chan
UNLABELLED: Tumor necrosis factor alpha (TNF) plays a critical role in the control of Mycobacterium tuberculosis, in part by augmenting T cell responses through promoting macrophage phagolysosomal fusion (thereby optimizing CD4(+) T cell immunity by enhancing antigen presentation) and apoptosis (a process that can lead to cross-priming of CD8(+) T cells). M. tuberculosis can evade antituberculosis (anti-TB) immunity by inhibiting host cell TNF production via expression of specific mycobacterial components...
May 31, 2016: MBio
https://www.readbyqxmd.com/read/27173443/boosting-bcg-primed-responses-with-a-subunit-apa-vaccine-during-the-waning-phase-improves-immunity-and-imparts-protection-against-mycobacterium-tuberculosis
#19
Subhadra Nandakumar, Sunil Kannanganat, Karen M Dobos, Megan Lucas, John S Spencer, Rama Rao Amara, Bonnie B Plikaytis, James E Posey, Suraj B Sable
Heterologous prime-boosting has emerged as a powerful vaccination approach against tuberculosis. However, optimal timing to boost BCG-immunity using subunit vaccines remains unclear in clinical trials. Here, we followed the adhesin Apa-specific T-cell responses in BCG-primed mice and investigated its BCG-booster potential. The Apa-specific T-cell response peaked 32-52 weeks after parenteral or mucosal BCG-priming but waned significantly by 78 weeks. A subunit-Apa-boost during the contraction-phase of BCG-response had a greater effect on the magnitude and functional quality of specific cellular and humoral responses compared to a boost at the peak of BCG-response...
May 13, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27156624/boosting-bcg-with-inert-spores-improves-immunogenicity-and-induces-specific-il-17-responses-in-a-murine-model-of-bovine-tuberculosis
#20
M Carmen Garcia-Pelayo, Daryan A Kaveh, Laura Sibly, Paul R Webb, Naomi C Bull, Simon M Cutting, Philip J Hogarth
Tuberculosis (TB) remains a global pandemic, in both animals and man, and novel vaccines are urgently required. Heterologous prime-boost of BCG represents a promising strategy for improved TB vaccines, with respiratory delivery the most efficacious to date. Such an approach may be an ideal vaccination strategy against bovine TB (bTB), but respiratory vaccination presents a technical challenge in cattle. Inert bacterial spores represent an attractive vaccine vehicle. Therefore we evaluated whether parenterally administered spores are efficacious when used as a BCG boost in a murine model of immunity against Mycobacterium bovis...
May 2016: Tuberculosis
keyword
keyword
35438
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"